Steven Gelone
Director/Miembro de la Junta en NABRIVA THERAPEUTICS PLC .
Fortuna: 20 454 $ al 31/07/2023
Cargos activos de Steven Gelone
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
NABRIVA THERAPEUTICS PLC | Director/Miembro de la Junta | 01/03/2021 | - |
Director de Operaciones | 24/07/2018 | 15/01/2023 | |
Director Técnico/Científico/I+D | 30/06/2017 | 24/07/2018 | |
Corporate Officer/Principal | 23/06/2017 | 30/06/2017 | |
Presidente | 24/07/2018 | 15/01/2023 |
Historial de carrera de Steven Gelone
Antiguos cargos conocidos de Steven Gelone.
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
Nabriva Therapeutics GmbH
Nabriva Therapeutics GmbH Pharmaceuticals: MajorHealth Technology Nabriva Therapeutics GmbH is a clinical-stage biopharmaceutical company, which engages in the research and development of novel anti-infective agents to treat serious infections. It focuses on the pleuromutilin class of antibiotics. The company was founded by Rodger Novak in October 2005 and is headquartered in Vienna, Austria. | Director Técnico/Científico/I+D | - | 30/06/2017 |
Corporate Officer/Principal | 01/01/2014 | - | |
Shire ViroPharma, Inc.
Shire ViroPharma, Inc. Pharmaceuticals: MajorHealth Technology Shire ViroPharma, Inc. develops and manufactures drugs. It offers treatment for prophylaxis of hereditary angioedema, as well as capsules for the treatment of antibiotic associated pseudomembranous colitis caused by Clostridium difficile infection (CDI) and enterocolitis. The company was founded by Claude H. Nash and Mark A. McKinlay in September 1994 and is headquartered in Exton, PA. | Corporate Officer/Principal | 01/01/2005 | 01/01/2014 |
Vicuron Pharmaceuticals LLC
Vicuron Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Vicuron Pharmaceuticals LLC develops pharmaceutical products. It engages in discovering, developing, manufacturing, and commercializing vital medicine for seriously ill patients. The company offers anidulafungin drug, which prevents cell wall formation and other infectious fungi. It also offers antibiotic for the treatment of complicated skin and soft-tissue infections. The company was founded by Christopher T. Walsh in 1995 and is headquartered in King of Prussia, PA. | Director Técnico/Científico/I+D | 01/01/2002 | 01/01/2003 |
GSK PLC | Director Técnico/Científico/I+D | 01/01/2000 | 01/01/2002 |
SPARK THERAPEUTICS, INC. | Director Técnico/Científico/I+D | 01/01/2014 | - |
Formación de Steven Gelone.
Temple University (Pennsylvania) | Doctorate Degree |
Estadísticas
Internacional
Estados Unidos | 5 |
Austria | 2 |
Irlanda | 2 |
Operativa
Chief Tech/Sci/R&D Officer | 5 |
Corporate Officer/Principal | 3 |
Doctorate Degree | 1 |
Sectorial
Health Technology | 7 |
Consumer Services | 2 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
Empresas cotizadas | 2 |
---|---|
NABRIVA THERAPEUTICS PLC | Health Technology |
GSK PLC | Health Technology |
Empresas privadas | 4 |
---|---|
Nabriva Therapeutics GmbH
Nabriva Therapeutics GmbH Pharmaceuticals: MajorHealth Technology Nabriva Therapeutics GmbH is a clinical-stage biopharmaceutical company, which engages in the research and development of novel anti-infective agents to treat serious infections. It focuses on the pleuromutilin class of antibiotics. The company was founded by Rodger Novak in October 2005 and is headquartered in Vienna, Austria. | Health Technology |
Spark Therapeutics, Inc.
Spark Therapeutics, Inc. BiotechnologyHealth Technology Spark Therapeutics, Inc. engages in the research, development, and commercialization of gene therapies. Its product portfolio intends to treat inherited retinal sickness, liver-mediated, and neurodegenerative diseases. The company was founded by Jean Bennett, Beverly Davidson, Katherine A. High, Jeffrey D. Marrazzo, J. Fraser Wright, and Jennifer Wellman on March 13, 2013 and is headquartered in Philadelphia, PA. | Health Technology |
Shire ViroPharma, Inc.
Shire ViroPharma, Inc. Pharmaceuticals: MajorHealth Technology Shire ViroPharma, Inc. develops and manufactures drugs. It offers treatment for prophylaxis of hereditary angioedema, as well as capsules for the treatment of antibiotic associated pseudomembranous colitis caused by Clostridium difficile infection (CDI) and enterocolitis. The company was founded by Claude H. Nash and Mark A. McKinlay in September 1994 and is headquartered in Exton, PA. | Health Technology |
Vicuron Pharmaceuticals LLC
Vicuron Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Vicuron Pharmaceuticals LLC develops pharmaceutical products. It engages in discovering, developing, manufacturing, and commercializing vital medicine for seriously ill patients. The company offers anidulafungin drug, which prevents cell wall formation and other infectious fungi. It also offers antibiotic for the treatment of complicated skin and soft-tissue infections. The company was founded by Christopher T. Walsh in 1995 and is headquartered in King of Prussia, PA. | Health Technology |
- Bolsa de valores
- Insiders
- Steven Gelone
- Experiencia